Physician profile
Ann Lindgren
NPI 1275544751
$4,889.65
in general payments reported to CMS, 2019-2025
32 companies · $581 in 2025
The $581 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $135 · 2021: $19.43 · 2022: $352 · 2023: $1,759 · 2024: $1,296 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,416 · Education: $220.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,416.04 |
| Education | $219.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $501.73 | 2019-2025 | Aklief, Oracea, Epsolay |
| Janssen Biotech, INC. | $433.84 | 2019-2025 | Tremfya |
| Genzyme Corporation | $397.74 | 2020-2025 | |
| Incyte Corporation | $364.03 | 2022-2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $363.31 | 2023-2025 | Zoryve |
| Pfizer INC. | $357.91 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $349.30 | 2019-2024 | Ilumya, Winlevi, Absorica Ld |
| Novartis Pharmaceuticals Corporation | $301.62 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $267.62 | 2023 | Sotyktu |
| Amgen INC. | $240.28 | 2023-2025 | Otezla, Otezla |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $197.94 | 2019-2024 | Jublia, Arazlo, Duobrii |
| Abbvie INC. | $166.26 | 2022-2025 | |
| Mayne Pharma Commercial LLC | $129.78 | 2019-2023 | |
| Verrica Pharmaceuticals INC. | $99.16 | 2023-2024 | Ycanth |
| Dermavant Sciences, INC. | $92.26 | 2023-2024 | Vtama |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $91.79 | 2022-2023 | Seysara |
| Ucb, INC. | $73.43 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $71.54 | 2023 | Dupixent |
| Leo Pharma INC. | $66.48 | 2023-2024 | Adbry |
| Sebela Pharmaceuticals INC. | $43.99 | 2022-2023 | Naftin |
| Lilly USA, LLC | $36.32 | 2023 | Olumiant, Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.11 | 2024 | Spevigo |
| Mission Pharmacal Company | $31.22 | 2019 | |
| Journey Medical Corporation | $27.18 | 2019-2022 | |
| Organon LLC | $23.62 | 2025 | Vtama |
| Biofrontera INC. | $22.57 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Sandoz INC. | $20.21 | 2019 | |
| Encore Dermatology INC. | $19.72 | 2019 | |
| Kyowa Kirin, INC. | $19.52 | 2023 | Poteligeo |
| Dermira, INC. | $17.69 | 2019 | |
| Botanix Sb INC | $15.05 | 2025 | Sofdra |
| Prugen, INC. Pharmaceuticals | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ann Lindgren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.